It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).
AMGN (@Pharmaceuticals: Major) experienced а -2.68% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.78% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.62%. For the same industry, the average monthly price growth was -3.07%, and the average quarterly price growth was -2.90%.
AMGN is expected to report earnings on Feb 04, 2025.
BMY is expected to report earnings on Feb 06, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
AMGN | BMY | AMGN / BMY | |
Capitalization | 152B | 110B | 138% |
EBITDA | 14.8B | 19.4B | 76% |
Gain YTD | -5.792 | 17.382 | -33% |
P/E Ratio | 22.66 | 13.73 | 165% |
Revenue | 28.2B | 45B | 63% |
Total Cash | 10.9B | 12.3B | 89% |
Total Debt | 64.6B | 41.5B | 156% |
AMGN | BMY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 39 | 71 | |
SMR RATING 1..100 | 18 | 96 | |
PRICE GROWTH RATING 1..100 | 63 | 43 | |
P/E GROWTH RATING 1..100 | 16 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (10) in the Pharmaceuticals Major industry is in the same range as AMGN (18) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (39) in the Biotechnology industry is in the same range as BMY (71) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
AMGN's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for BMY (96) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than BMY’s over the last 12 months.
BMY's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as AMGN (63) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for BMY (94) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than BMY’s over the last 12 months.
AMGN | BMY | |
---|---|---|
RSI ODDS (%) | 1 day ago56% | N/A |
Stochastic ODDS (%) | 1 day ago55% | 1 day ago50% |
Momentum ODDS (%) | N/A | 1 day ago54% |
MACD ODDS (%) | 1 day ago59% | 1 day ago48% |
TrendWeek ODDS (%) | 1 day ago57% | 1 day ago52% |
TrendMonth ODDS (%) | 1 day ago50% | 1 day ago54% |
Advances ODDS (%) | 1 day ago54% | 5 days ago55% |
Declines ODDS (%) | 4 days ago53% | 3 days ago55% |
BollingerBands ODDS (%) | 1 day ago66% | 1 day ago64% |
Aroon ODDS (%) | 4 days ago49% | 1 day ago45% |
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
---|---|---|---|---|
AMGN | 100% | +0.84% | ||
PFE - AMGN | 35% Loosely correlated | +2.29% | ||
BIIB - AMGN | 33% Loosely correlated | -0.62% | ||
ABBV - AMGN | 29% Poorly correlated | +2.37% | ||
JNJ - AMGN | 27% Poorly correlated | +0.62% | ||
OGN - AMGN | 26% Poorly correlated | +0.97% | ||
More |
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
---|---|---|---|---|
BMY | 100% | +1.83% | ||
PFE - BMY | 39% Loosely correlated | +2.29% | ||
JNJ - BMY | 39% Loosely correlated | +0.62% | ||
ABBV - BMY | 34% Loosely correlated | +2.37% | ||
GILD - BMY | 32% Poorly correlated | +1.62% | ||
RHHBY - BMY | 30% Poorly correlated | +0.76% | ||
More |